The ARF protein product of the ink4a/arf locus is induced by a variety of oncogenic signals. ARF facilitates growth arrest through the p53 pathway by hindering the down-regulation of p53 activity mediated by MDM2, through the formation of a protein complex with MDM2. Here we have explored the possibility that human p14 ARF activity is integrated with growth regulating pathways other than p53, and report our results that p14 ARF can control the activity of the E2F transcription factor. p14
Introduction
The ink4a/arf locus is frequently mutated in human cancer Sherr, 1998) . In humans, the locus encompasses two independent but overlapping genes that encode two proteins, p16
INK4a and p14 ARF (Quelle et al., 1995) . The p16 INK4a protein acts through the pathway of control governed by the retinoblastoma tumour suppressor protein pRb which, in normal cells, negatively regulates the G1 to S phase transition (Dyson, 1998; Sherr, 1998) . p16
INK4a blocks the activity of cyclinD/cdk4 kinase by binding to the catalytic cdk subunit, thus preventing pRb phosphorylation and retaining pRb in a hypo-phosphorylated and growthsuppressing state (Serrano et al., 1993; Sherr, 1998) . The principal target through which pRb regulates growth is believed to be the E2F transcription factor, which plays an important role in controlling the transcriptional activity of genes required for cells to progress into S phase (Dyson, 1998) .
On the other hand, ARF expression appears to act as a sensor for oncogenic signals and cause growth arrest by modulating the activity of the p53 tumour suppressor protein through interfering with the regulation of p53 by MDM2 (Palmero et al., 1998; Pomerantz et al., 1998; Zhang et al., 1998) . MDM2 binds to p53 through a motif located in the p53 transcriptional activation domain, thereby preventing the activation of p53 target genes (Ko and Prives, 1996) . The control of p53 activity requires the E3 ubiquitin ligase of MDM2, which stimulates the ubiquitin-dependent degradation of p53, together with the relocalization of p53 to the cytosol (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997; Roth et al., 1998; Tao and Levine, 1999) . Through the physical interaction with MDM2, ARF is believed to act to prevent the down-regulation of p53 (Honda and Yasuda, 1999) .
Transcription of the ARF gene can be induced through a variety of oncogenic stimuli, including viral oncoproteins such as adenovirus E1A, and cellular oncogenes, like c-Myc, Ras and E2F-1 (Bates et al., 1998; De Stanchina et al., 1998; Dimri et al., 2000; Schmitt et al., 1999; Zhang and Xiong, 1999) , although oncogenic Ras does not induce arf expression in human cells (Wei et al., 2001) . Under these conditions, p14
ARF binds to and blocks MDM2 activity, thereby inducing p53 levels and thereafter the p53 response resulting in cell cycle arrest or apoptosis (Sherr, 1998) . A part of this mechanism may involve ARF causing MDM2 to relocalise to nucleoli (Serrano et al., 1993; Zhang and Xiong, 1999; Lohrum et al., 2000; Llanos et al., 2001) .
A transcriptional regulator of ARF expression appears to be E2F-1 (Bates et al., 1998) . The human ARF promoter, located in exon 1b of the ink4a/arf locus, contains several potential E2F binding sites, and it has been shown that E2F-1 can increase ARF promoter activity (Bates et al., 1998) . The induction of ARF expression by E2F-1 may help explain the observed co-operation between E2F-1 and p53 in the induction of apoptosis (Bates et al., 1998; Dyson, 1998) .
A number of studies have suggested that MDM2, ARF, and p53 are not necessarily connected only through a single linear pathway. For example, MDM2 activity is integrated with the pRb/E2F pathway (Martin et al., 1995; Xiao et al., 1995; Loughran and La Thangue, 2000) ; MDM2 can regulate E2F activity in p53
7/7 cells (Loughran and La Thangue, 2000) and form a protein complex with pRb (Xiao et al., 1995) . These observations are consistent with results from EmMyc transgenic mice which develop tumours that harbour mutations in the murine p19 ARF and p53 loci, but overexpress MDM2 (Eischen et al., 1999) . Moreover, ARF-dependent growth arrest has been shown to be dependent not only upon the activity of p53, but also the control of the pRb pathway (Carnero et al., 2000) . Furthermore, the reintroduction of p19 ARF into triple knockout (in arf, p53 and mdm2) MEFs arrests cell cycle progression in G1, an eect that is not alleviated by the subsequent inhibition of pRb by the HPV E7 oncoprotein (Weber et al., 2000a) .
Given the increasing evidence for a role for the pRb pathway in the growth regulating eects of ARF, together with the suggestion that a target for ARF lies downstream of pRb, we reasoned that E2F may be a candidate target for regulation by ARF. This idea led us to explore the role of p14 ARF in E2F control, and here we report that indeed p14 ARF can regulate E2F activity. We ®nd that p14 ARF down-regulates E2F-1 activity, and further that this eect correlates with the inhibition of E2F-dependent apoptosis. p14 ARF forms a physical complex with E2F-1, and multiple binding domains reside in p14 ARF for E2F-1. A domain in the N-terminal region of p14 ARF , that can be distinguished from a previously identi®ed MDM2 binding domain, is capable of autonomously down-regulating E2F activity. These results de®ne E2F-1 as a target in p14 ARFdependent growth control. In addition, they imply a model in which the E2F-1-regulation of arf transcription is subject to negative auto-regulation by ARF protein.
Results

p14
ARF regulates E2F-dependent apoptosis
Previous studies suggested that human MDM2 (hDM2) can modulate the apoptotic activity of E2F (Loughran and La Thangue, 2000) . In SAOS2 tumour cells, which are p53 7/7 /Rb 7/7 , the introduction of E2F-1 and DP-1, two subunits of the E2F heterodimer Dyson, 1998) , into growth-arrested cells resulted in signi®cant levels of apoptosis, which could be overcome upon the coexpression of hDM2 ( Figure 1a ). As we previously reported, the ability of hDM2 to down-regulate E2F-dependent apoptosis correlates with an hDM2-dependent growth stimulation (Loughran and La Thangue, 2000) .
We performed a similar experiment to study the eect of p14 ARF upon E2F-dependent apoptosis and found, to our surprise, that exogenous ARF could reduce the level of cells undergoing apoptosis ( Figure  lb) . Whilst of considerable interest, nevertheless this result was not anticipated, as we would have expected that p14 ARF , through its interaction with endogenous hDM2 (Sherr, 1998) , would overcome the downregulation of E2F to augment E2F activity. Indeed, it is consistent with this prediction that in conditions of hDM2 down-regulation of E2F-dependent apoptosis, that co-expressing p14 ARF overcame the anti-apoptotic activity of hDM2 (Figure 1c) . These results suggest that p14
ARF may possess activities involved in regulating hDM2 and the control of E2F activity.
Whilst previous studies have shown that hDM2 and E2F can co-operate in cell cycle progression (Loughran and La Thangue, 2000) , it was important to assess the consequence of the p14 ARF down-regulation of E2F activity on the cell cycle. Thus, we studied the kinetics of cell cycle progression by¯ow cytometry. In SAOS2 cells the introduction of wild-type p53 caused an increase in the size of the sub-G1 DNA content apoptosing population of cells, and the co-expression of E2F-1 and DP-1 likewise resulted in an induction of sub-G1 cells (Figure 1d ). Most importantly, the coexpression of p14 ARF with E2F-1 and DP-1 abrogated the sub-G1 population of cells, favouring the accumulation of cells in G1 (Figure 1d ). That this eect was dependent upon p14 ARF activity was supported by the action of hDM2, which overcame p14 ARF activity resulting in an induction of sub-G1 cells (Figure 1d ). The combined conclusion from these results argues that p14 ARF can regulate E2F-dependent apoptosis.
ARF can down-regulate E2F-dependent transcription
The results suggest that p14 ARF can regulate the apoptotic activity of E2F-1. Because E2F-dependent apoptosis in part requires E2F transcriptional activity Lissy et al., 2000) , the results in turn raised the possibility that p14 ARF may in¯uence the ability of E2F to activate target genes. We tested this idea by studying the eect of p14 ARF on dierent E2F-responsive promoters, including the p14 ARF promoter located in exon1b of arf (Bates et al., 1998) , cyclinE (Botz et al., 1996) , apaf1 (Moroni et al., 2001 ) and 36WT, an arti®cial promoter containing three tandem E2F sites (Zamanian and La Thangue, 1992) ; representative examples of the results are presented.
In SAOS2 cells the exon1b promoter was induced by E2F-1 and DP-1, and the co-introduction of p14 ARF caused a striking reduction in transcriptional activity (Figure 2a ). This activity was abolished by the presence of hDM2, which overcame the p14-dependent reduction ( Figure 2b ). An eect was observed on the other E2F responsive promoters, including cyclinE, Apaf1 and 36WT (Figure 2c , d, and data not shown), and there was little change in E2F or p14 ARF protein levels in co-transfected cells (Figure 2e ). Thus, the observed eect was a p14 ARF on E2F-dependent apoptosis and cell cycle progression (Figure 1 ), and are consistent with the idea that p14 ARF can regulate E2F activity, and that this regulation is responsible for mediating the eects on E2F-dependent apoptosis. The eect of p14 ARF was reproducibly less striking on the cyclinE promoter compared to the exon 1b and Apaf1 promoters, the reasons for which remain to be elucidated.
ARF regulates E2F activity in p53 7/7 /mdm2 7/7
MEFs
Whilst the results derived from SAOS2 cells suggest that p14 ARF regulates E2F activity, because SAOS2 are tumour cells that express hDM2 and may harbour unknown genetic lesions that aect ARF activity, it was not possible to rule out that the observed eects of p14 ARF on E2F were mediated through hDM2 or other genetic abnormalities. To exclude this possibility, we studied the eect of p14 ARF on BrdU incorporation and E2F-dependent transcription in early passage p53 7/7 /mdm2 7/7 MEFs. Exogenous p14 ARF reduced the level of BrdU incorporation (Figure 3a) , a result that concurs with other recent studies on the eect of murine p19 ARF in p53 7/7 /mdm2 7/7 MEFs (Weber et al., 2000a) . In addition, the p14 ARF reduction in BrdU incorporation was apparent when E2F-1 and DP-1 were introduced into the cells and E2F-1/DP-1 could overcome the eect of ARF on BrdU incorporation ( Figure 3a) . Similarly, in p53 7/7 /mdm
MEFs p14 ARF could down-regulate the transcriptional activity of E2F-1 on the 36WT and exon 1b promoter ( Figure  3b ). The overall conclusion from the studies performed in SAOS2 cells and p53 7/7 /mdm2 7/7 MEFs implies that p14
ARF can reduce E2F activity, and that it does ARF regulates E2F target genes. (a) SAOS2 cells were transfected with expression vectors for E2F-1 (50 ng), DP-1 (500 ng), and p14 (250 ng, 500 ng, 750 ng, 1 mg) together with the exon 1b-luc reporter (500 ng). Cells were harvested 40 h posttransfection with each treatment performed in duplicate. CMV-bgal (500 ng) was included as an internal control. The data shown represents the ratio of luciferase to b galactosidase, and is representative of at least three independent experiments. (b) SAOS2 cells were transfected with expression vectors for E2F-1 (50 ng), DP-1 (500 ng), p14 (1 mg) and hDM2 (1 mg) together with the exon 1b-luc reporter (500 ng) as indicated, and treated as described in a. (c) SAOS2 cells were transfected with expression vectors for E2F-1 (50 ng), DP-1 (500 ng) and p14 (2 and 4 mg) as indicated, together with the cyclinE-luc reporter (500 ng), and treated as described in a. (d) SAOS2 cells were transfected with expression vectors for E2F-1 (50 ng), DP-1 (500 ng), and p14 (2 and 4 mg) as indicated, together with the Apa¯(7396/+208)-luc reporter (500 ng), and treated as described in a. (e) SAOS2 cells were transfected with expression vectors for E2F-1 (50 ng) and p14 (2 mg) as indicated, and at 40 h post-transfection harvested. Immunoblotting for E2F-1 and p14 was performed as described so in a fashion that is mechanistically and functionally independent of p53 and MDM2.
p14
ARF can physically interact with E2F-1
The most likely mechanism to explain the eect of p14 ARF on E2F activity was that an interaction between ARF and E2F was in part responsible. We tested this idea by investigating if ARF could bind to E2F-1 in SAOS2 cell and p53
MEF extracts. Relative to the control GST treatment, we found that GST-p14 ARF bound to E2F-1 in both cell extracts (Figure 4a ).
Next, we demonstrated an association between p14 ARF and E2F under physiological conditions by performing immunoprecipitation from HeLa cells with anti-p14 or anti-E2F-1 followed by immunoblotting with anti-hDM2, anti-E2F-1 or anti-p14. In p14 ARF immunoprecipitates hDM2, E2F-1 and p14 ARF were present, and similarly in the reciprocal immunoprecipitation with anti-E2F-1 (Figure 4b ). Thus, p14
ARF and E2F-1 can associate under physiological conditions. The observed co-immunoprecipitation was not due to the presence of hDM2, as E2F-1 was undetectable in anti-hDM2 immunoprecipitates (Figure 4b ). / mdm2 7/7 MEFs were transfected with expression vectors for E2F-1 (500 ng) and p14 (500 ng) together with p36WT-luc (1 mg), p36MT-luc (1 mg) or the exon1b-luc (4 mg) reporter as indicated. Cells were harvested at 40 h post-transfection with each treatment performed in duplicate. CMV-bgal (500 ng) was included as an internal control. The data shown represents the ratio of luciferase to b galactosidase, and is representative of at least three independent experiments (Figure 5a ). Wildtype E2F-1 could bind to GST-p14 ARF , and analysing the binding properties of the series of E2F-1 mutants Figure 5 p14 ARF binds to E2F-1. (a) Diagram summarising the E2F-1 derivatives; CYA shows the position of the cyclinA binding domain, and act/pp the trans activation and pocket protein binding domain (Helin et al., 1993) . (b) The indicated E2F-1 derivatives were in vitro translated and incubated with GST-p14 (1 mg) or GST (1 mg) protein. Reactions were washed and subjected to SDS ± PAGE gel analysis as described. (c) The indicated E2F-1 derivatives were treated as described in b. Note that the results in (b) and (c) were derived from experiments performed in parallel, and re¯ect equivalent exposure times. (d) Puri®ed His-E2F-1 (0.5 mg) was incubated with puri®ed GST, GST-DP-1 or GST-p14 (0.5 mg) and thereafter binding between the indicated proteins assessed by immunoblotting with either anti-p14 ARF (tracks 1, 2 and 4) or anti-DP-1 (track 3) mapped an interaction domain to the central region of E2F-1, encompassing a part of the DNA binding domain, from residue 181 to 261 (Figure 5a ). However, E2F-1 181 ± 261 reproducibly exhibited reduced binding to GST-p14 ARF compared to wild-type E2F-1 (reduced by about 75%), suggesting that this region approached the minimal ARF binding domain.
Furthermore, although the results derived from the in vitro binding assays are consistent with a direct interaction between E2F-1 and p14 ARF , we could not rule out an indirect association mediated through another unidenti®ed protein. To test this possibility, we assessed the binding of puri®ed GST-DP-1 or GSTp14 ARF to His-E2F-1. As expected, there was a direct and speci®c interaction between E2F-1 and DP-1 and, in addition, speci®c binding was reproducibly observed between E2F-1 and p14 ARF (Figure 5d ). These results therefore support the idea that p14 ARF and E2F-1 can directly interact.
Binding domains in p14
ARF for E2F-1
To elucidate the regions in p14 ARF that are involved in binding to and the control of E2F, we undertook both a functional and biochemical study. In the initial analysis, we utilized two derivatives of p14 ARF , representing the N-and C-terminal halves of the protein (Figure 6a ) and assessed their activity upon the E2F-1-dependent activation of the exon1b promoter. Whereas the C-terminal half had negligible eect, a clear reduction in E2F-1 activity was seen upon expression of the N-terminal half (Figure 6b ). These results imply that the N-terminal half of p14 ARF is functionally important in regulating E2F-dependent transcription.
In order to resolve further the interaction domains, we studied the properties of a panel of p14 ARF derivatives (Figure 6a ) which were co-expressed together with E2F-1 in SAOS2 cells and thereafter immunoprecipitated. An interaction was evident between wild-type p14 ARF and E2F-1, and both the Nand C-region domains bound to E2F-1 (Figure 6c ). Since the functionally relevant interaction domain in E2F control was located in the N-terminal half ( Figure  6b ), we further analysed this region and mapped the minimal N-terminal binding region to within 34 residues, since a p14 derivative encompassing residues 1 to 34, but not one containing residue 1 to 22, was capable of binding to E2F-1 (Figure 6c ).
The N-terminal E2F binding domain in p14
ARF regulates E2F activity
Since the C-terminal half of p14 ARF fails to regulate E2F activity, we focussed on the minimal binding domain mapped to the N-terminal region, and asked if this domain was sucient to regulate E2F-1 activity. In a similar fashion to the eect of wild-type p14 ARF , we found that residues 1 to 34 could down-regulate E2F activity. Furthermore, as anticipated from the lack of binding between residue 1 to 22 there was no apparent down-regulation when this mutant was co-expressed with E2F-1 (Figure 7d ). In fact, p14 1 ± 22 was frequently observed to stimulate E2F activity, perhaps because of a dominant-negative action on endogenous ARF activity.
Overall, the analysis of the ARF mutant derivatives mapped a functionally important p14 ARF /E2F-1 interaction domain to the N-terminal 34 residues of ARF. Since there was a correlation between this ARF/E2F-1 binding domain and reduced E2F activity, the results suggest that a physical interaction is required for the p14 ARF -dependent down-regulation of the E2F activity.
Discussion
p14 ARF regulates E2F
ARF is a protein of central importance in cell cycle control. ARF expression is induced by the action of diverse oncogenic signals, culminating in cell cycle arrest, apoptosis or senescence Sherr, 1998 ). An established mechanism through which ARF hinders proliferation is through the physical interaction with MDM2 to prevent the destabilization of p53, and thereby facilitate the p53 response (Pomerantz et al., 1998; Zhang et al., 1998) . The interaction between ARF and MDM2 may involve the sequestration of MDM2 to a nucleolar location, although the importance of this process of relocalization for ARF function remains unclear Zhang and Xiong, 1999; Lohrum et al., 2000; Llanos et al., 2001; Lomax and Fried, 2001; Korgaonkar et al., 2002) . MDM2 is clearly an important target in mediating the eects of ARF, although mechanisms other than the direct regulation of MDM2 have been suggested based upon a variety of studies (Carnero et al., 2000; Weber et al., 2000b) . Perhaps most compelling are those studies which document ARF activity in the absence of an intact MDM2/p53 pathway. Thus, murine p19 ARF can induce senescence in p53 7/7 MEFs (Carnero et al., 2000) , and in triple knock-out p53 7/7 / mdm 7/7 /arf 7/7 MEFs causes growth inhibition (Weber et al., 2000b) .
Previous studies have established a connection between MDM2 activity and G1 to S phase control by the pRb/E2F pathway. For example, by forming a complex with pRb, MDM2 can hinder pRb-dependent growth inhibition (Xiao et al., 1995) . Further, MDM2 can interact with E2F and down-regulate apoptosis in favour of cell cycle progression (Loughran and La Thangue, 2000) . Indeed, these earlier studies led us to investigate the role of ARF in the control of E2F activity.
The results presented in this study strongly suggest that human p14 ARF can eect E2F activity in a fashion that results in E2F down-regulation. That this eect of p14 ARF was observed in p53 7/7 /mdm2 7/7 cells argues that an intact p53/MDM2 pathway is not essential for the process. Moreover, in the conditions of our investigation exogenous p14 ARF led to ecient cell cycle arrest, whilst interfering with the level of E2F-dependent apoptosis, a result which at a general level agrees with recent reports (Russell et al., 2002) . These results highlight a signi®cant dierence between the regulation by ARF of the p53 and E2F pathways. Speci®cally, by blocking the interaction between MDM2 and p53, ARF facilitates diverse outcomes, 1 ± 64 or p14 65 ± 132 (1 mg) and the exon 1b-luc reporter (500 ng). Cells were harvested 40 h posttransfection and each treatment performed in duplicate. CMV-bgal (500 ng) was included as an internal control. The data shown represent the ratio of luciferase to b galactosidase, and are representative of three independent experiments. (c) SAOS2 cells were transfected with expression vectors for E2F-1 (10 mg) alone or together with the indicated p14 derivatives (10 mg). Extracts were prepared and immunoprecipitated with anti-E2F-1 antibody and immunoblotted with anti-myc (for p14, indicated by *) or anti-HA (for E2F-1, indicated by *). Each pair of tracks shows the input (IN) and immunoprecipitate (IP). Note that tracks 1 to 10, and tracks 11 and 12, were derived from separate SDS gels. (d) SAOS2 cells were transfected with expression vectors for E2F-1 (50 ng) and DP-1 (500 ng) alone or together with the indicated p14 derivatives (1 mg) and the exon 1b-luc reporter (1 mg). Cells were harvested and treated as described in a including apoptosis and cell cycle arrest (Quelle et al., 1995; Chin et al., 1998; Sherr, 1998; Dimri et al., 2000) . In contrast, p14 ARF regulation of E2F appears to favour cell cycle arrest at the expense of apoptosis.
p14 ARF binds to E2F
Whilst the mechanism through which p14 ARF regulates E2F activity remains to be determined, the results presented here suggest that p14 ARF can associate with E2F under physiological conditions, a conclusion based upon results derived from a variety of in vitro and cellbased studies. Furthermore, an interaction domain was mapped to the central region of the E2F-1, in the region of the DNA binding domain. In this respect, whilst ARF-dependent regulation of MDM2 has been connected with an ARF-dependent relocalization of MDM2 to a nucleolar location Zhang and Xiong, 1999; Lohrum et al., 2000; Llanos et al., 2001) , we have failed to detect signi®cant relocalization of E2F-1 under the conditions of p14 ARF expression in our experimental conditions (data not shown).
Our results are in general agreement with recently published studies documenting a physical interaction between ARF and certain E2F family members, resulting in E2F destabilization and regulation (Eymin et al., 2001; Martelli et al., 2001) . However, these studies were performed in cell-types in which the MDM2 gene remained intact, suggesting a role for MDM2 in the observed eects. The results presented here strengthen the evidence for the interplay between ARF and E2F, but also formally rule out a role for MDM2 and p53 in this process, as p14 ARF was seen to regulate E2F activity when both mdm2 and p53 were genetically inactivated, most probably through the direct interaction between p14 ARF and E2F-1. Another noteworthy observation is the location in the N-terminal 34 residues of p14 ARF required for the interaction with E2F-1. A nucleolar localization signal and MDM2 binding domain exists in the N-terminal 22 residues of p14 ARF Lohrum et al., 2000) , although this region was not sucient to bind to and regulate E2F-1 (Figure 6 ). Nevertheless, the close proximity of the E2F-1 and MDM2 binding domains in the N-terminal region of p14 ARE does not exclude the possibility that under certain conditions E2F-1 and MDM2 may compete for ARF.
Auto-regulation of arf expression
Our results suggest a model in which arf transcription is subject to auto-regulation through the ARF protein.
Speci®cally, the E2F-dependent activation of the exon 1b promoter will be in¯uenced by ARF protein as its levels increase through transcription of arf. We envisage as the levels of ARF increase, that ARF functionally interacts with MDM2. It is possible that subsequent increases in ARF, target and functionally inactivate E2F, and thereafter lower arf transcription (Figure 7) . This model provides an autoregulatory mechanism in which arf expression is subject to negative control by ARF once the levels of MDM2 have been titrated and inactivated.
At a general level, our results oer an explanation for the eects of ARF in cells lacking functional p53 and MDM2 (Carnero et al., 2000; Weber et al., 2000b) , which we would argue are likely to be mediated through the regulation of E2F activity. Moreover, the identi®cation of E2F as a target of ARF control de®nes ARF with a speci®c and perhaps more direct role in the control of the G1 to S phase transition.
Materials and methods
Plasmids and expression vectors
The following plasmids have been previously described; HA-E2F1 (Helin et al., 1992) , E2F1Y411C (Helin et al., 1993) , CMV-DP1 , CMVp14 ARF (Bates et al., 1998) , pchDM2 (Loughran and La Thangue, 2000) , pCMVbgal (Zamanian and La Thangue, 1992), pcDNA3-mycp 14, pcDNA3mycN62, pcDNA3mycC65 (44) , TxARF 1 ± 132, 1 ± 22, 1 ± 34, 1 ± 64, and 65 ± 132 (Lohrum et al., 2000) . pGEXp14
ARF was prepared by digesting CMVp14 ARF and cloning the fragment into the BamH1/EcoRI site in pGEX KG (Pharmacia). HA-E2F-1 181 ± 280 and HA-E2F-1 141 ± 280 were prepared by PCR ampli®cation using the following pairs of primers: Forward -141 -GGGGATCC-GAGCTGCTGAGCCACTCGGCT and reverse GGTCTA-GAC TCCGAAGAGTCCACGGCTTG, and forward -181 -GGGGATCC# GCCAAGAA GTCCAAGAACCAC and reverse GGTCTAGACTCCGAAGAGTCCACGGCTTG the ampli®ed fragments being subsequently cloned into pcDNA3.
Transient transfection and reporter assays
Transfection was carried out in SAOS2 cells or early passage p53 7/7 /mdm2 7/7 mouse embryo ®broblasts (MEFs) grown in DMEM by the calcium phosphate procedure (as Figure 7 Regulation of E2F activity by ARF. It is envisaged that the E2F-dependent transcriptional activation of arf gives rise to levels of ARF protein that target and inactivate MDM2 (a). Increasing levels of ARF titrate our MDM2 and, through the interaction with E2F, down-regulate arf expression (b). This model provides an autoregulatory mechanism for the control of ARF protein levels p14 ARF regulates E2F activity SL Mason et al previously described; Loughran and La Thangue, 2000; Morris et al., 2000) ; 500 ng CMV-bgal was included as an internal control per 6 cm plate. The quantity of DNA per transfection was kept constant by the addition of pcDNA3 or pSG5 empty vector; assays were performed at least in duplicate. The following reporters were used; Exon 1b-luc (Bates et al., 1998) , Apa¯(7396/+208)-luc (Moroni et al., 2001) , cyclinE-luc (Botz et al., 1996) , 36WT and 36MT (Zamanian and La Thangue, 1992) .
Recombinant proteins
The following GST and His-tagged proteins were expressed in BL21 and puri®ed as previously described; GST-DP1, GST-p14 ARF and His-E2F1 Girling et al., 1993) .
Cell extracts and biochemical assays
Nuclear extracts were prepared from SAOS2 cells and early passage p53 7/7 /mdm2 7/7 MEFs by scraping monolayers and swelling in buer (20 mM HEPES, 20% glycerol, 250 mM NaCl 2 , 1.5 mM MgCl 2 , 1 mM EDTA, 0.1% Triton X) for 30 min, and centrifugation at 2000 r.p.m. for 10 min before lysis in 50 mM Tris pH 8.0, 150 mM NaCl 2 , 5 mM EDTA, 0.5% NP40 on ice. Supernatants were collected by centrifugation and thereafter used for biochemical binding assays where nuclear extract (about 200 mg) was incubated with the GST protein (about 1 mg) at 48C. Binding reactions were carried out in TNE (50 mM Tris pH 8.0, 150 mM NaCl 2 , 5 mM EDTA, 0.5% NP40 containing 1 mM DTT, 1 mM PMSF and protease inhibitors). Glutathione beads were washed three times and resuspended in SDS buer for gel electrophoresis. For in vitro translated proteins derived from the T7 TNT coupled system (Promega), an equal amount of translated protein was added to GST protein (about 1 mg) in 200 ml buer. Reactions were incubated at 48C and then washed three times before being resuspended in SDS buer for gel electrophoresis. For the in vitro binding assay using GST proteins, about 1 mg of puri®ed protein (as indicated) was incubated in 50 mM Tris, 150 mM NaCl 2 , 5 mM EDTA, 0.5 mM NP40 with His-E2F1 for 1 h at 48C.
TUNEL and BrdU incorporation
For TUNEL assays SAOS2 cells (3610 5 ) were plated onto coverslips and transfected with each of the indicated plasmid (about 6 mg) as described previously (Loughran and La Thangue, 2000) . Following transfection, the cells were washed twice in PBS and serum starved (0.2% serum) overnight. Cells were ®xed for 15 min in 4% paraformaldehyde and permeabalized for 10 min in 0.1% Triton, 0.1% sodium citrate in PBS. TUNEL was performed as described by the manufacturer (Roche). Cells were counted a minimum of three times under low and high power uorescence microscopy, and normalized for transfection eciency. Transfection eciency was determined by immunostaining cells with a relevant antibody against an exogenous protein.
For the BrdU assay p53 7/7 /mdm2 7/7 MEFs (1610 5 ) were plated on coverslips and transfected with each plasmid (about 5 mg). Following transfection cells were washed twice in PBS and left overnight in DMEM containing 10% FCS. BrdU labelling was carried out for 15 min at 378C and cells were then ®xed in ethanol: glycine buer (pH 2.0) for a minimum of 30 min at 7208C, and stained according to the BrdU Labelling Kit 1 (Roche). BrdU was detected by staining with anti-BrdU. Cells were mounted and examined as described for the TUNEL assay. Transfection eciency was determined by including pCMV-bgal (about 6 mg) in the transfection and monitoring b galactosidase activity.
Flow cytometry
SAOS2 cells were transfected with the indicated plasmids (about 10 mg) and the CD20 expression vector (about 4 mg) and harvested 24 h post-transfection. Cells were suspended in 200 ml DMEM, and incubated with the anti-CD20 antibody for 45 min. Cells were washed twice in PBS, ®xed in 50% ethanol/PBS and stored overnight at 48C. Samples were washed twice in PBS before the addition of 100 mg/ml of RNase and 50 mg/ml of propidium iodide. Cell cycle analysis was performed on a Becton Dickinson cell sorter using the CellQuest software (BD) as described previously (Morris et al., 2000) . Relative percentage change in cell cycle progression was calculated with respect to the mock (empty vector) control.
Immunoprecipitation and immunoblotting
For the immunoprecipitation of endogenous protein complexes HeLa cell nuclear extracts (500 mg) were incubated with anti-E2F-1 (KH95, Santa Cruz), anti-p14 (C18, Santa Cruz), anti-MDM2 (H221, Santa Cruz), or anti-HA (HA11, BabCo) antibody in a total volume of 100 ml TNE overnight at 48C with rotation. Protein A agarose was then added to the samples, and further incubated for 3 h at 48C with rotation. Immunoprecipitates were washed in TNE binding buer and re-suspended in SDS loading buer, and subsequently analysed by SDS ± PAGE and immunoblotting with the appropriate antibody.
